1 Impairment in endothelial cell (EC) function plays a central role in vascular diseases (e.g. atherosclerosis, restenosis, diabetic angiopathies, microvascular angina, peripheral arterial disease). BRX-235 (a novel small molecule synthesized by Biorex, Hungary) has a potent vasculoprotective activity in dierent in vivo and in vitro studies. Since the importance of the p38 pathway in EC homeostasis and migration in particular is well documented, we have carried out studies to address the role of the p38 stress activated protein kinase (p38 SAPK) in the mode of action of BRX-235. In this study, Bovine aortic endothelial cells were used in a wounding migration assay (WMA) and for Western-blot analysis to study the eect and molecular mechanism of BRX-235-induced EC migration. 2 The bovine aortic endothelial (BAE) cells were shown to be good models for EC migration. 3 Both endothelial cell growth factor (ECGF)-and BRX-235-induced BAE cell migration were shown to be inhibited by SB 203580, a speci®c inhibitor of p38 SAPK. 4 It was also shown that, BRX-235 induces phosphorylation of p38 SAPK without aecting p38 SAPK protein levels. Thus, BRX-235 acts upstream of p38 SAPK. 5 In summary, we have shown that p38 SAPK is a potential pharmacological mediator for candidate drugs that target the endothelium.
Introduction
Endothelial cells (EC) play a critical role in vascular homeostasis through the release of variety of autocrine and paracrine substances. They sense and integrate hemodynamic stimuli and regulate hemostasis and in¯ammation. Impairment in EC function plays a central role in many vascular diseases (e.g. reperfusion injury, atherosclerosis, restenosis, diabetic angiopathies, microvascular angina, peripheral arterial disease). Angioplasty denudes the vessel of endothelial cells that would normally generate paracrine inhibitors of vascular smooth muscle cell (VSMC) migration and proliferation.
Endothelial repair and angiogenesis involve EC migration and proliferation. Migration may in fact be responsible for subsequent proliferation by formation of regions of low cell density or by removal of inhibitory mechanisms due to cell ± cell contact. EC migration is dependent on the p38 SAPK activation in basic-®broblast growth factor (bFGF) (Tanaka et al., 1999) and VEGF (Rousseau et al., 2000) treated cells. Structural evidence has been published that endothelial cell growth factor (ECGF) is the precursor of ®broblast growth factor (FGF) (Burgess et al., 1986) . In aortic vessels bFGFinduced EC proliferation is mediated by p38 (Rousseau et al., 2000) . The importance of the p38 pathway is further accentuated by the ®ndings showing that induction of endothelial transfer substance-1 (Ets-1), the major coordinator of gene expression during reendothelization after denuding injury, is mediated through p38 (Tanaka et al., 1998) .
SB 203580 is one of the pyridinyl imidazole derivatives, which inhibits the activity of mitogen activated protein kinase (MAPK). In vivo it suppresses the activation of MAPK activated protein kinase-2 (MAPKAPK-2) and prevents the phosphorylation of the 27 kDa heat shock protein (Hsp27) in response to interleukin-1, cellular stress and bacterial endotoxin (Cuenda et al., 1995) . Inhibition by SB 203580 implicated p38 SAPK in the migration of endothelial cells (Rousseau et al., 1977) . Bimoclomol 1 (Biorex, Hungary) has been shown to aect the stress signal transduction pathways through stimulation of p38 SAPK (Balla et al., 1999; Kreuzer, 1999) .
The stress response is a complex process and involves multiple signalling pathways. The ERK (extra-cellular signalregulated kinase) pathway primarily transmits mitogenic and dierentiation stimuli, whereas the JNK (c-Jun N-terminal kinase) and p38 pathways mainly transduce stress stimuli to nucleus. All three mitogen-activated protein kinases (MAPK) subfamilies play important roles in several functions. The expression of phosphorylated p38 SAPK in epithelial and myogenic cell lines (ECV and H9c2) increased by induction of H 2 O 2 and was potentiated by Bimoclomol 1 (Balla et al., 1999) . On the other hand, translocation of JNK and ERK was not aected either in human SMC (smooth muscle cells) (Kreuzer, 1999) or in EC (unpublished data).
BRX-235 is a member of a new family of non-toxic hydroxylamine-based compounds that originated with Bimoclomol 1 (VõÂ gh et al., 1997; NaÂ naÂ si & JednaÂ kovits, 2001). BRX-235 was recently developed in the research laboratories of Biorex R&D. Co. (Hungary) for treatment of atherosclerosis and the complications of atherosclerosis such as ischaemic heart disease, peripheral arterial disease and restenosis. The chemical structure of BRX-235 is 5,6-dihydro-5-(1-piperidinyl) methyl-3-(3-pyridil)-4H-1,2,4-oxadiazine (Figure 1 ).
Here we show that BRX-235 is a potent inducer of BAE cell migration, an eect that is believed to be behind the EC repair capability of BRX-235. We also show that BRX-235 mediates this action via p38 SAPK phosphorylation.
Methods

Reagents
Chemicals were obtained from Sigma Chemicals Co. (St. Louis, MO, U.S.A.) unless otherwise indicated. The pyridinyl imidazole (SB 203580), a speci®c inhibitor of p38 SAP kinase activity (Lee et al., 1994) , was obtained from Upstate Biotech. Inc. (La Jolla, CA, U.S.A.).
Isolation and cultivation of bovine aortic endothelial (BAE) cells
A section of bovine aorta was placed into sterile PBS-solution containing an antibiotic mixture and was incubated at room temperature for 60 min. Trypsin-EDTA solution (Sigma) was layered on the inner surface of a piece of aortic vessel and endothelial cells were digested at 378C for 15 min, washed and resuspended in RPMI 1640 (Gibco-BRL, U.S.A.) containing 20% FCS (Sigma). The isolated and stained cells were von Willebrand (Factor VIII) positive endothelial cells. BAE cells were seeded in a 96-well plate for wounding migration assay (WMA). The cell count was adjusted to 1 ± 2610 6 cells ml 71 and 1 ml of cell suspension was layered in a 6-well plate (Costar, U.S.A.) for phosphorylation studies.
Wounding migration assay
The assay was carried out as described previously (Yamamura et al., 1996) . BAE cells were seeded in the 96-well plate and, at approximately 90% con¯uency, the monolayer was wounded with a scraper (width=1 mm) along a horizontal line. Wells were rinsed with completed RPMI 1640 medium with 2% FCS and incubated at 378C in 5% CO 2 . Cells migrating to the wounded area were counted 0, 4, 24, and 48 h after wounding using a computerized image analysis software (KSK2 software; Pictron, Hungary). The number of cells in the wounded area was expressed as the number of occupied pixels. For monitoring the eects of BRX-235 (Biorex, Hungary) and MAP Kinase inhibitor (SB 203580) on migration of BAE cells, reagents were diluted in the medium and added to the cells after wounding.
Western blot analysis
For protein blotting BAE cells were cultivated in 6-well plates (Costar, U.S.A.). The con¯uent monolayers were wounded along 10 lines at the start of the experiment. At indicated times cells were scraped o using a rubber policeman (Costar) with 10 ml ice-cold PBS (pH=7.4) and collected by centrifugation at 10006g for 4 min at 48C. Pellets were homogenized by ultrasound homogenizer (Branson Sonifer 450) for 15 s at 08C in 100 ± 150 ml lysis buer containing (mM): Tris HCl 50 (pH=8), EDTA 5, NaCl 150, phenylmethylsulphonyl¯uoride 1, benzamidine 1, aminocaproic acid 1, ocadaic acid 10, NaF 50, Na-o-vanadate 5, 0.1% sodium dodecyl sulphate and 1% Triton X-100. Lysates were centrifuged at 16,0006g for 5 min at 48C and the supernatants were placed on ice. The protein concentration was determined according to Bradford (1976) and samples were stored at 7808C until further use.
Twenty micrograms of protein was electrophoresed on a 12% SDS-polyacrylamide gel (SDS ± PAGE) using a minislab gel apparatus (Bio-Rad, U.S.A.). The separated proteins were transferred onto a polyvinylidene¯uoride (PVDF) membrane (Immobilon P, Millipore, U.S.A.) blocked with 5% skim milk in Tris buer salt (TBS, pH=7.4) containing 0.1% Tween 20, for 1 h at room temperature. Membranes were probed with anti-phospho-p38 antibody by commercially available kits (PhosphoPlus p38 MAP kinase Antibody Kit, New England Biolabs, U.S.A.) overnight at 48C. Analysis of threonine and tyrosine phosphorylation of p38 SAPK was performed according to the manufacturer's instructions. After probing with the secondary peroxidaselabelled antibody at room temperature for 1 h, proteins were visualized using enhanced chemiluminescence (ECL) and exposing them to ECL Hyper®lm (Amersham, U.K.). In order to show the amounts of p38 SAPK, blots were stripped and reprobed using phosphorylation-state independent p38 SAPK-speci®c anti-p38 antibody to determine total p38 SAPK levels.
Statistical evaluation
The number of migrated cells was given in pixels (150,000 pixel points=3 mm 2 surface) and values were also expressed in percentages. The means+s.e.mean were calculated. Comparisons between groups were assessed by Student's ttest. Statistical signi®cance was de®ned as *P50.05; **P50.01; ***P50.005.
Results
Migration of bovine aortic endothelial cells is mediated by the p38 SAPK pathway
In this study the migration of BAE cells was assessed. Migration was induced by mechanical wounding of the BAE cell layer. By 48 h post-wounding a signi®cant increase in migration was recorded (Figure 2a ). This spontaneous migration was signi®cantly inhibited by submicromolar (at 10, 100 and 1000 nM) concentration of SB 203580. At 1 mM concentration the spontaneous migration was inhibited by 60%. This correlates well with data published on human umbilical venous endothelial cells (HUVEC) (Rousseau et al., 1997) .
To validate our system we studied the eect of the endothelial cell growth supplement (ECGFs) on BAE cell migration. ECGF is a rich source of endothelial cell growth factor (Maciag et al., 1982) , a potent mitogen and an inducer of EC migration. ECGFs at a dilution of 1 : 25 signi®cantly stimulated the migration of BAE cells, while the 1 : 100 fold dilution had only a slight eect (Figure 2b) . SB 203580 at 1 mM potently inhibited endothelial cell growth factor supplement (ECGFs)-induced BAE cell migration compared to the control value (Figure 2c) .
Induction of the migration of BAE cells by BRX-235
BRX-235 dose-dependently stimulated BAE cell migration at 10, 100 and 1000 nM (26.5, 63.3 and 73.5% respectively) ( Figure 3) .
Next we studied the potential role of p38 SAPK in the mechanism of BRX-235-stimulated BAE cell migration using SB 203580. SB 203580 was used at 1 mM concentration that has been shown to inhibit eciently the BAE cell migration both on spontaneous (Figure 2a ) and ECGFs-induced cells ( Figure  2c ). However, SB 203580 potently inhibited migration induced by 10 and 100 nM BRX-235 (90 and 76%, respectively) ( Figure  4) . Inhibition was less profound (38%) when BRX-235 was used at 1 mM). Thus, involvement of the p38 SAPK pathway is a common theme in the mechanism of spontaneous, ECGFsand BRX-235-induced BAE cell migration. 
Phosphorylation of p38 SAPK by BRX-235
The increases in threonine-and tyrosine-phosphorylation of p38 SAPK re¯ect the activation state of p38 SAPK. Thus, the threonine-and tyrosine-phosphorylation of p38 SAPK upon BRX-235 treatment was examined. BAEC-s were stimulated with BRX-235 (1 mM) for 10, 20, 30 and 240 min and lysates were immunoblotted for p38 SAPK. Following treatment with BRX-235 the amount of phosphorylated p38 SAPK (pp38 SAPK) increased 1.78 fold after 10 min, 1.98 fold after 20 min, and declined after 240 min ( Figure 5 ). ECGF induced p38 SAPK phosphorylation by about the same extent as BRX-235 but with dierent kinetics (Figure 5 ). The amount of p38 SAPK did not change following BRX-235 treatment, indicating that the BRX-235 acts on the p38 SAPK signalling pathway upstream of the kinase.
In order to examine the eect of BRX-235 induced p38 SAPK phosphorylation we performed Western blots utilizing an anti-pp38 SAPK antibody that detects active forms of the kinase. Cells were incubated with BRX-235 (1, 10, 100 and 1000 nM) for 15 min, and the amounts of phosphorylated p38 SAPK were determined. Phosphorylated p38 SAPK increased The lysates were run on a 12% SDS ± PAGE. After probing, the membranes were developed with anti-pp38 SAPK (upper panel); Membranes were stripped and reprobed using a phosphorylation state-independent p38 SAPK-speci®c antibody (lower panel). (b) The amount of pp38 SAPK from BAE cells were studied after stimulation with BRX-235 (BRX, 1 mM), and ECGFs (GF, 25 fold diluted) or without BRX-235 (EC) for 30 and 240 min as indicated. The amounts of pp38 SAPK were quanti®ed with an image analytical system (Multi-Analyst software, Bio-Rad, CA, U.S.A.). The increase over control is given. Blots are representative of three experiments. (c) Dose-dependent activation of p38 SAPK by BRX-235. BAE cells were stimulated with BRX-235 (lanes 4, 5, 6, 7; 1, 10, 100 and 1000 nM respectively), ECGFs (GF 25 fold diluted, lane 3), vehicle (EC, lane 2) and lysate prepared from anisomycin stimulated C-6 glioma cells as positive control (P, lane 1) for 15 min. Lysates were run on a 12% SDS ± PAGE. After probing the membrane with antipp38 SAPK (upper panel), membranes were stripped and reprobed using a phosphorylation state-independent p38 MAPK-speci®c antibody. The amounts of pp38 SAPK were quanti®ed with an image analysis system (Multi-Analyst software, Bio-Rad, CA, U.S.A.). The increase over control is given. In the ®gure the blots illustrate the data and results of three experiments.
after BRX-235 treatment in a dose-dependent manner (Figure 5c, upper panel) . After a 15 min exposure, BRX-235 (at 1 nM) slightly activated p38 SAPK. The lower panel of Figure 5c shows that, regardless of culture conditions, equal amounts of p38 SAPK protein were immunoblotted using a phosphorylation state-independent p38 SAPK-speci®c antibody.
Phosphorylated-p38 SAPK activities with SB 203580 and BRX-235
The inhibitor, SB 203580 has not modulated the phosphorylation status of p38 SAPK neither in untreated nor in BRX-235 (1 mM, line B1) or ECGFs-stimulated cells (Figure 6 , line GF). The phosphorylation status (pp38/p38) only decreased slightly upon exposure to SB 203580 in BRX-235 stimulated cells (1.67 vs 1.82) and in ECGFs-treated cells (1.58 vs 1.62).
Discussion
Both spontaneous and growth factor-induced migration of BAE cells is mediated by the p38 SAPK pathway (Figure 2 ). This correlates well with data from studies on HUVEC (Rousseau et al., 1977; . We also presented evidence that BRX-235, a drug candidate to treat endothelial dysfunction, is a potent inducer of EC migration ( Figure  3) . Earlier studies have shown that BRX-235 signi®cantly reduced the intima thickness in Apo-E de®cient mice, improved endothelial dysfunction and induced EC recovery in spontaneously hypertensive animals (unpublished data). Using SB 203580, a p38 SAPK speci®c inhibitor, we demonstrated that the stimulation of EC migration by BRX-235 is also mediated by p38 SAPK (Figure 4) . Western blots have shown that BRX-235 stimulates phosphorylation of p38 SAPK at pharmacological dose ranges ( Figure 5 ). The transient nature of this stimulation supports the notion that BRX-235 modi®es stress signalling. Therefore BRX-235 acts upstream of p38 SAPK to induce BAE cell migration. Our data show (Figure 6c ) that SB 203580 does not interfere with either the basal or the BRX-235 or ECGF-induced phosphorylation of p38 SAPK con®rming that SB 203580 primarily acts on activated p38 SAPK (Kumar et al., 1997; 1999) , although contradicting reports have also been published (Armstrong et al., 1999) .
Bimoclomol 1 potentiates the activation and the accumulation of all major classes of heat shock proteins, including Hsp60, Hsp70, Hsp90 and GRP94 (glucose regulated protein 94) (VõÂ gh et al., 1998) and BRX-235 has been shown to have a similar, or a slightly lower eect in connection with Hsp70 at pharmacologically equivalent doses in several cell-lines (3T3, ECV, A715, H9C2, PC12, etc.) (unpublished data).
p38 SAPK stabilizes the micro®laments in cells by activation of Hsp27. This leads to phosphorylation regulated F-actin polymerization and changes of the actin cytoskeleton that result in the motility of endothelial cells (Rousseau et al., 1997) . Bimoclomol 1 , a close analogue of BRX-235, with pharmacologically similar pro®le activates p38 phosphoryla- Figure 6 Eect of BRX-235 with SB 203580 on phosphorylated-p38 SAPK. BAE cells were treated with SB 203580 (SB 1 mM, line 1) or with p38 inhibitor and another agent, either BRX-235 (SB+B 1 mM each, line 3) or ECGFs (SB+GF 1 mM and 25 fold diluted, line 4) for 30 min. The lysates of BAE cells after incubation (for 30 min at 378C in air containing 5% CO 2 ) were run on a 12% SDS ± PAGE either exposed with agents or cells without treatment (EC, line 2), transferred to membranes, and probed with a speci®c antibody directed against the phosphorylated threonine and tyrosine of p38 SAPK (phospho-p38 SAPK; upper panel). These blots were reprobed using a phosphorylation state independent p38 SAPK speci®c antibody. The amounts of p38 SAPK are visualized in the lower strip (p38 SAPK; lower panel). In SB 203580-treated BAE cells the amounts of phosphorylated p38 SAPK decreased. Amounts of pp38 SAPK were higher in cells treated with SB 203580 and with either BRX-235 (SB+B1) or ECGFs (SB+GF) than in untreated (EC) control cells. The phosphorylated status of p38 SAPK have been expressed (pp38 SAPK/p38 SAPK) and depicted on ®gure. tion without aecting ERK or JNK phosphorylation (Balla et al., 1999; Kreuzer, 1999) . p38 SAPK but not JNK and ERK regulates the activation of cytoskeletal alpha-actin in mechanical stress (Lew et al., 1999) . Because of this notion, the activation of ERK and JNK by BRX-235 has not been speci®cally checked. Several authors have found parallelism or contradictory eect on the activation of p38 and JNK in various models (Schiaonati et al., 2001; Recio & Merlino, 2002; Chaturvedi et al., 2002; Montaner & Perez-Thomas, 2002; Dougherty et al., 2002; Fleisher et al., 2001; Surapisitchat et al., 2001) . Bimoclomol 1 potentiates stressinduced Hsp induction without aecting the overall heat shock factor 1 (HSF1) phosphorylation and it is known that JNK phosphorylation is followed by HSF1 phosphorylation (Park & Liu, 2001 and unpublished data) . Additional experiments related to ERK and JNK activation are in progress. On the other hand SB 203580 inhibited the migration of BAE cells at concentration as low as 10 nM (Figure 2a ). At this concentration we believe SB 203580 is speci®c for p38 SAPK.
Four isoforms of p38 MAPKs have been identi®ed in mammalian cells, which are all phosphorylated and activated by MKK6 (MAPK kinase 6). In addition, MMK3 activates p38 SAPKa, p38 SAPKg, and p38 SAPKd, whereas MKK4 can only activate p38 SAPKa isomer (Nebreda & Porras, 2000) . These kinases are speci®c for p38 SAPK (Igarashi et al., 2000) . Thus, BRX-235 can target MKK6/3 to activate the p38 SAPK pathway. Alternatively, BRX-235 might directly bind p38 SAPK making it a better substrate for upstream kinases.
SB 203580 has been shown to be speci®c for p38 SAPKa and p38 SAPKb isoforms (Wang et al., 1998) . Our data showing that SB 203580 eciently inhibits EC migration is correlated with data of the literature and con®rm that p38a and p38b isoforms play a dominant role in EC migration (Azuma et al., 2001; Hedges et al., 1999; Rousseau et al., 1997) .
Vascular endothelial growth factor (VEGF) and the basic ®broblast growth factor (bFGF) are being developed to treat a variety of vascular diseases due to their stimulatory eect on EC migration and proliferation (Gibbons, 1996) . Both VEGF (Rousseau et al., 2000) and bFGF induce p38 activation. p38 SAPK is thought to orchestrate re-endothelization after angioplasty. It has been shown that reendothelization limits neointima formation and subsequent restenosis (Ohashi et al., 2000) . p38 SAPK has also been shown to mediate myocardial adaptation to ischaemia (Maulik et al., 1998) . Nuclear factor kB (Maulik et al., 1998) , Hsp27 (Armstrong et al., 1999; Craig et al., 2000) and mitochondrial K(ATP) channels (Baines et al., 1999) have all been shown as downstream eectors of p38 SAPK to mediate ischaemic preconditioning. Although re-endothelization and angiogenesis are distinct phenomena with respect to regulation and function, the mechanisms are partly overlapping. However, angiogenesis is a double-edged sword so we studied the angiogenic eect of BRX-235 using the chicken chorioallantoic membrane system. The compound showed no angiogenic eect at any of the pharmacological and supra pharmacological doses tested (unpublished data).
In summary, BRX-235-induced endothelial repair is mediated through the p38 SAPK pathway. p38 SAPKmediated EC migration certainly contributes favourably to the therapeutic eects of BRX-235 in atherosclerosis and restenosis.
